Ivabradine: New Drug For The Heart Patients Approved

.

Ivabradine: New Drug For The Heart Patients Approved

A new study carried out by a team of doctors has proved that Ivabradine drug can help reduce the deaths caused by heart failure to a great extent. It is estimated that heart failure affects 900,000 people in UK, causing 100,000 deaths a year. However, the results of this drug are estimated to decline the death rate by more than a third.

Professor Martin Cowie, Consultant Cardiologist at the Royal Brompton Hospital in London who led this study, carried out a clinical trial ‘Shift’ before effusing the life saving statements. The clinical trials carried out on the drug showed that it abates the possibilities of death from heart failure by 39% and thus cutting the rate of hospital admissions by 24%.

A case that was considered while clinical trials added to the success story of this drug. Anne Tanner, who was diagnosed with heart failure in 2007, was put on this drug as part of her medication. The treatment has changed her life completely. She states that she is able to perform all the activities that she was unable to carry out before the treatment.

The main causes that doctors analyze in case of heart failure are articulated to be heart attack, that weaken the heart and due to this the pumping system is also damaged. As a result, there is a less supply of blood and thus oxygen to the heart. This drug further, acts by slowing down the heart beat. This action in turn helps the heart to pump oxygenated blood more efficiently. This drug is already used to treat angina.

The European Medicine Regulator, after beholding the consequences of the drug has approved its use for patients dealing with heart failure. This drug will be launched at a price rate that will cost no more than £1.50 a day, thus costing less than £10 a week.


Latest News

Rise in Russian Arms Sales In spite of a Drop Globally
PetSmart Sells itself with an $8.3Billion Deal
Falling Oil Prices Result in a Drop in Stocks
Shares of Amaya Fall Due to Probe Conducted by Securities Regulators
Americans Consumers Display Confidence In the Market with Gain in Sales
It’s Time to Hurry Up to Enrol in the First Phase of Affordable Care Act Health
After Merger with Alliance Boots,	Walgreen CEO will Retire
Falling Fuel Prices Lift Airline Profits But No Respite in Fares Expected
Citigroup to Pay Likely $2.7B as Legal Charge
Michael Jeffries Retires as the CEO of Abercrombie & Fitch
Deutsche Bank in Trouble Again in the U.S. for Alleged Tax Scheme
Popular Demand Brings French Toast Crunch Back on the Shelves